Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Kathleen A. Fairman
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 26:371-374
Results of the carefully executed Evaluation of Treatment with Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer (ERACER) study, reported in this issue, echo those of several previous observational analyses of the association of lo
Autor:
Patricia Bonazzola, Germán A. Colareda, Alicia E. Consolini, Matías Bayley, María Inés Ragone
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 25:72-85
Hypothyroidism is considered a cardiac risk factor, but there is controversial evidence about its effects on coronary disease. The aim of this work was to evaluate the influence of hypothyroidism in rat hearts exposed to 2 degrees of stunning due to
Autor:
Abdel Rahman El-Naggar, Mohammed F. El-Yamany, Dalia K Zaafar, Soha Osama Hassanin, Hekma A. Abdel-Latif, Atef Bassyouni
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 24:254-261
Background: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors are used to improve endothelial function in addition to treating type 2 diabetes (T2DM). The current study investigated the effects of vildagliptin, DPP-4 inhibit
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 23:216-225
Oxidative stress and inflammation are associated with endothelial injury and coronary artery disease. Inflammatory factors that promote oxidative damage include endothelin-1 (ET-1), myeloperoxidase (MPO), and C-reactive protein (CRP). Current guideli
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 23:66-78
Although the contributions of sitagliptin to endothelial function in diabetes mellitus were previously reported, the potential mechanisms still remain undefined. Our research was intended to explore the underlying mechanisms of protective effects of
Autor:
Jun Yoshioka, Bing F. Wang
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 22:219-229
Myocardial ischemia/reperfusion injury represents a major threat to human health and contributes to adverse cardiovascular outcomes worldwide. Despite the identification of numerous molecular mechanisms, understanding of the complex pathophysiology o
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 22:153-158
Background: Cardiac troponins (cTn) are reliable and the most sensitive biomarker in the setting of acute decompensated heart failure (ADHF). Acute decompensated heart failure is usually associated with worsening chronic heart failure, and it may be
Autor:
Zhi-Dong Ge, Martin K. Childers, Muhammad Afzal, David L. Mack, Allison D. Ebert, Jered V. McGivern, Xuan Guan, Courtney Gastonguay, Melanie Reiter, Jennifer L. Strande
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 21:549-562
Background: Dystrophin-deficient cardiomyopathy is a growing clinical problem without targeted treatments. We investigated whether nicorandil promotes cardioprotection in human dystrophin-deficient induced pluripotent stem cell (iPSC)-derived cardiom
Autor:
Uğur Abbas Bal, Ali Gökhan Özyıldız, Serpil Eroglu, Kaan Okyay, Haldun Muderrisoglu, Ilyas Atar
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 22:65-70
Background and aim: Beta-blockers have unfavorable effects on metabolic parameters in hypertensive treatment. New generation beta-blockers with vasodilatory capabilities are superior to traditional beta-blockers, but studies examining their effects o
Autor:
Yawei Ji, Jianhua Zhu, Richard M. Breyer, Shuang Liu, Jian Yao, Xiaodan Zhao, Hu Xu, Hongzhuan Sheng, Youfei Guan
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 22:71-82
Background: Prostaglandin E2 receptor subtype 3 (EP3), a Gi protein-coupled receptor activated by prostaglandin E2, plays a particular role in cardioprotection. This study aimed to investigate the impact of EP3 deletion on cardiac remodeling and furt